US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Clovis Oncology, Inc. - Common Stock
(NQ:
CLVS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 20, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clovis Oncology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 18, 2022
Gainers HOOKIPA Pharma (NASDAQ:HOOK) stoc...
Via
Benzinga
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
February 10, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
January 10, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
December 09, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
63 Biggest Movers From Friday
↗
December 20, 2021
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...
Via
Benzinga
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
↗
November 16, 2021
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices.
Via
InvestorPlace
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
November 03, 2021
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...
Via
FinancialNewsMedia
Clovis Oncology Announces Third Quarter 2021 Operating Results
November 03, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
October 20, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
October 19, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
October 07, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
September 20, 2021
Via
FinancialNewsMedia
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
September 20, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Why Clovis Oncology Shares Got a Bump This Week
↗
August 27, 2021
Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.
Via
The Motley Fool
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
August 16, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 04, 2021
Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6...
Via
Benzinga
Clovis Oncology Announces Second Quarter 2021 Operating Results
August 04, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
↗
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
July 21, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 14, 2021
Gainers Qualigen Therapeutics (NASDAQ:QLGN) stock moved upwards by 8.98% to $1.94 during Wednesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
26 Stocks Moving in Wednesday's Pre-Market Session
↗
July 14, 2021
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) shares rose 35.6% to $3.54 in pre-market trading after jumping around 12% on Tuesday. Oxbridge Re Holdings Limited (NASDAQ: OXBR) shares...
Via
Benzinga
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
July 12, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
What's Going On With Clovis Oncology Stock?
↗
July 12, 2021
Clovis Oncology Inc. (NASDAQ: CLVS) shares gapped up Monday morning but have since fallen back to trading down on the day. There looks to be no company news acting as a catalyst...
Via
Benzinga
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
June 29, 2021
Via
FinancialNewsMedia
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
June 28, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
June 23, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
2 Great Reasons to Buy This Cancer Treatment Stock Now
↗
June 15, 2021
When future promise meets hype, it's hard to deny the potential.
Via
The Motley Fool
Here's Why Wall Street Is Betting Against Clovis Oncology
↗
June 12, 2021
The biotech is getting the sort of attention that its short-sellers would rather avoid.
Via
The Motley Fool
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
June 10, 2021
From
Clovis Oncology, Inc.
Via
Business Wire
62 Biggest Movers From Yesterday
↗
June 10, 2021
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
